• Something wrong with this record ?

Slow sulfide donor GYY4137 potentiates effect of paclitaxel on colorectal carcinoma cells

M. Kajsik, B. Chovancova, V. Liskova, P. Babula, O. Krizanova

. 2022 ; 922 (-) : 174875. [pub] 20220318

Language English Country Netherlands

Document type Journal Article

Although paclitaxel (PTX) is potent chemotherapeutic agent commonly used in variety of cancers, in colorectal carcinoma its usage is excluded because of low effectivity. Up to now, some experimental attempts were utilized to improve sensitivity of colorectal carcinoma to PTX. We used a slow sulfide donor GYY4137 to increase sensitivity of colorectal carcinoma cells to PTX. As a model of colorectal carcinoma, we utilized three different cell lines - HCT116, SW620 and DLD1. We compared IC50 for PTX and PTX/GYY4137, cell cycle, apoptosis, ATP levels and changes in intracellular pH. We observed significant decrease in IC50 levels in PTX/GYY4137 groups compared to PTX in all three cell lines. PTX arrested cell cycle in G2/M phase. Differences in S phase were observed in HCT116 and DLD1 cells treated with 20 nM PTX/GYY4137, but not in SW620 cell. GYY4137 increased early, but not late phase of apoptosis. This increase was not detected in non-cancer EAHy926 cells. Upregulation of IP3R1 suggested involvement of these receptors in PTX and/or GYY4137 induced apoptosis. We also observed partial ATP depletion and intracellular acidification in PTX treated groups. In PTX/GYY4137 groups of all three cell lines no ATP depletion was detectable and intracellular acidification was lower than in PTX treated groups. Slight differences in all measured parameters were determined among HCT116, SW620 and DLD1 cells, which is probably due to physiological variations in these cells. Taking together, sensitivity of PTX to colorectal carcinoma cell lines could be increased by slow sulfide donor GYY4137, probably through potentiation of apoptosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018459
003      
CZ-PrNML
005      
20220804134800.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejphar.2022.174875 $2 doi
035    __
$a (PubMed)35314158
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kajsik, Marek $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia; Department of Chemistry, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Namestie J. Herdu 2, 917 01, Trnava, Slovakia
245    10
$a Slow sulfide donor GYY4137 potentiates effect of paclitaxel on colorectal carcinoma cells / $c M. Kajsik, B. Chovancova, V. Liskova, P. Babula, O. Krizanova
520    9_
$a Although paclitaxel (PTX) is potent chemotherapeutic agent commonly used in variety of cancers, in colorectal carcinoma its usage is excluded because of low effectivity. Up to now, some experimental attempts were utilized to improve sensitivity of colorectal carcinoma to PTX. We used a slow sulfide donor GYY4137 to increase sensitivity of colorectal carcinoma cells to PTX. As a model of colorectal carcinoma, we utilized three different cell lines - HCT116, SW620 and DLD1. We compared IC50 for PTX and PTX/GYY4137, cell cycle, apoptosis, ATP levels and changes in intracellular pH. We observed significant decrease in IC50 levels in PTX/GYY4137 groups compared to PTX in all three cell lines. PTX arrested cell cycle in G2/M phase. Differences in S phase were observed in HCT116 and DLD1 cells treated with 20 nM PTX/GYY4137, but not in SW620 cell. GYY4137 increased early, but not late phase of apoptosis. This increase was not detected in non-cancer EAHy926 cells. Upregulation of IP3R1 suggested involvement of these receptors in PTX and/or GYY4137 induced apoptosis. We also observed partial ATP depletion and intracellular acidification in PTX treated groups. In PTX/GYY4137 groups of all three cell lines no ATP depletion was detectable and intracellular acidification was lower than in PTX treated groups. Slight differences in all measured parameters were determined among HCT116, SW620 and DLD1 cells, which is probably due to physiological variations in these cells. Taking together, sensitivity of PTX to colorectal carcinoma cell lines could be increased by slow sulfide donor GYY4137, probably through potentiation of apoptosis.
650    _2
$a adenosintrifosfát $x farmakologie $7 D000255
650    _2
$a apoptóza $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a kolorektální nádory $x patologie $7 D015179
650    _2
$a lidé $7 D006801
650    12
$a sulfan $x metabolismus $7 D006862
650    _2
$a morfoliny $7 D009025
650    _2
$a organothiofosforové sloučeniny $7 D009946
650    _2
$a paclitaxel $x farmakologie $7 D017239
650    _2
$a sulfidy $x farmakologie $x terapeutické užití $7 D013440
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chovancova, Barbora $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia
700    1_
$a Liskova, Veronika $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia
700    1_
$a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: babula@med.muni.cz
700    1_
$a Krizanova, Olga $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia; Department of Chemistry, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Namestie J. Herdu 2, 917 01, Trnava, Slovakia; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: olga.krizanova@savba.sk
773    0_
$w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 922, č. - (2022), s. 174875
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35314158 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134754 $b ABA008
999    __
$a ok $b bmc $g 1822172 $s 1169702
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 922 $c - $d 174875 $e 20220318 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...